Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent
- Written by PR Newswire
Landmark Agreement for New Tuberculosis Treatment
SEONGNAM-SI, South Korea and NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Qurient Co. Ltd. ("Qurient", KRX: 115180), a clinical-stage biotechnology company based in South Korea, and TB Alliance, a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and...














